# Product Data Sheet

Product Name: Protease-Activated Receptor-2, PAR-2 Agonist, amide

Catalog Number: AS-60217-5 (5 mg) Lot Number: See label on vial

Sequence: H-Ser-Leu-Ile-Gly-Lys-Val-NH2 (3-letter code)
SLIGKV-NH2 (1-letter code)

Molecular Weight: 615.8

% Peak Area by HPLC: ≥ 95

Appearance: Lyophilized white powder

Peptide Reconstitution: Using $H_2O$, reconstitute by adding 100 µl to 1 mg PAR peptide. This peptide is also soluble in 1%$NH_4OH$.

Storage: PAR peptide is shipped at ambient temperature. Upon receipt, store lyophilized peptide at –20°C or lower. Reconstituted peptide can be aliquoted and stored at –20°C or lower.

Description: This protease-activated receptor activating peptide (PAR-2-AP) corresponds to the PAR2 tethered ligand. Ref: Dulon et al. *Am. J. Resp. Cell Mol. Biol*. **28**, 339 (2003); Kim, M. et al. *Cell Biochem. Funct*. **20**, 339 (2002); Vesey, D. et al. *Kidney International* **67**, 1315 (2005); Hollenberg, M. Can. *J. Physiol. Pharmacol*. **75**, 832 (1997); Nishikawa, H. et al. *J. Pharmacol. Exp. Ther*. **312**, 324 (2005).

Additional Information: *Listed below are relevant information that may provide a guideline on how to use this product. End users will have to adapt to their own specific applications.*

Amidated PAR-activating peptides (PAR1 = AP-1 $NH_2$-TFLLRN-$NH_2$; PAR2 = AP-2 $NH_2$-SLIGKV-$NH_2$) were from Anaspec, Inc. Transfection of DU-145 cells with PAR1 and PAR2 SMARTpool (75 nmol/L) siRNAs (Dharmacon) or Silencer GAPDH siRNA (Ambion) with DharmaFECT1 (0.5 µL) was done with a modification of the double-transfection method. The cells were transfected for 5 h, the growth medium replaced, and the cells were treated with a second transfection after 24 h. The cells were reincubated (24 h) then shifted to serum-free medium prior to the ERK signaling assay-Mize, GJ. et al. *Mole. Cancer Res*. **6**, 1043 (2008).

Published Citations:


Ahn, H. et al. *Mol. Pharmacol.* **51**, 350 (1997).
Rauch, BH. et al. *Amer. Heart Assoc*. **94**, 340 (2004).
Black, PC. et al. *The Prostate* **67**, 743 (2007).
Mize, GJ. et al. *Mole. Cancer Res*. **6**, 1043 (2008).
Mize, GJ. et al. *Protein Expression & Purification* **57**, 280 (2008).
Wilson, TJ. et al. *Cancer Res.* **69**, 3188 (2009).

Related Products:

| Name | Cat # | Size |
|---|---|---|
| Protease-Activated Receptor-1, PAR-1 Agonist, amide (TFLLRNPNDK-NH2) | AS-62936 | 1 mg |
| Protease-Activated Receptor-1, PAR-1 Agonist, amide (TFLLRN-NH2) | AS-62937 | 5 mg |
| Protease-Activated Receptor-1, PAR-1 Agonist (TFLLRN) | AS-61530 | 1 mg |
| Protease-Activated Receptor-3, PAR-3 Agonist, amide (SFNGGP-NH2) | AS-62938 | 1 mg |
| Protease-Activated Receptor-3 (1-6), PAR-3 (1-6), human (TFRGAP-NH2) | AS-62657 | 1 mg |
| Protease-Activated Receptor-4, PAR-4 Agonist, amide (AYPGKF-NH2) | AS-60218-1<br>AS-60218-5 | 1 mg<br>5 mg |
| Protease-Activated Receptor-4, PAR-4 Agonist, amide, murine (GYPGKF-NH2) | AS-60778 | 1 mg |

*For Research Use Only*